Vol 72, No 1 (2022)
Research paper (original)
Published online: 2022-02-09

open access

Page views 5396
Article views/downloads 589
Get Citation

Connect on Social Media

Connect on Social Media

Secondary prevention and treatment of cervical cancer – an update from Poland

Patryk Poniewierza1, Marcin Śniadecki2, Michał Brzeziński2, Dagmara Klasa-Mazurkiewicz2, Grzegorz Panek3
Nowotwory. Journal of Oncology 2022;72(1):20-25.

Abstract

Introduction.Cervical cancer is the 4th most common cancer in terms of incidence and mortality in women worldwide. The aim of the study was to investigate and analyze the effects of Poland’s publicly funded cervical cancer screening and treatment programs.

Material and methods.The study analyzed the financial and epidemiological data provided by the Polish National Health Fund and the Polish National Cancer Registry on the prevention and treatment of cervical cancer in Poland in 2011–2017.

Results.Our study identified a systematic reduction in the number of patients undergoing cervical cytology. Despite high levels of financial expenditure, no correlation was found between the total cost of benefits in PLN million (W = 0.911; p = 0.404) and mortality expressed by the standardized coefficient (W = 0.884; p = 0.243).

Conclusions.Despite decreasing mortality rates in cases of cervical cancer in Poland, the organization and delivery of prevention and treatment programs should be considered insufficient.

Article available in PDF format

View PDF Download PDF file

References

  1. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3): 209–249.
  2. Wojciechowska U, Didkowska J, Michałek I. Cancer in Poland in 2018. Polish National Cancer Registry, Warsaw 2020.
  3. Nowakowski A, Arbyn M, Turkot MH, et al. A roadmap for a comprehensive control of cervical cancer in Poland: integration of available solutions into current practice in primary and secondary prevention. Eur J Cancer Prev. 2020; 29(2): 157–164.
  4. Nowakowski A, Turkot M, Miłosz K. Should we continue population-based cervical cancer screening programme in Poland? A statement in favour. Nowotwory. Journal of Oncology. 2018; 68(2): 108–112.
  5. de Rycke Y, Tubach F, Lafourcade A, et al. Cervical cancer screening coverage, management of squamous intraepithelial lesions and related costs in France. PLoS One. 2020; 15(2): e0228660.
  6. Wojciechowska U, Didkowska J. Changes in five-year relative survival rates in Poland in patients diagnosed in the years 1999–2010. Nowotwory. Journal of Oncology. 2018; 67(6): 349–358.
  7. Sant M, Lopez MC, Agresti R, et al. Survival of women with cancers of breast and genital organs in Europe 1999–2007: Results of the EUROCARE-5 study. European Journal of Cancer. 2015; 51(15): 2191–2205.
  8. Devarapalli P, Labani S, Nagarjuna N, et al. Barriers affecting uptake of cervical cancer screening in low and middle income countries: A systematic review. Indian J Cancer. 2018; 55(4): 318–326.
  9. Screening, survival and mortality for cervical cancer. Health at a Glance: Europe. 2018: 158–159.
  10. Arbyn M, Castellsagué X, de Sanjosé S, et al. Worldwide burden of cervical cancer in 2008. Ann Oncol. 2011; 22(12): 2675–2686.
  11. Turkot M, Mokwa D, Wieszczy P, et al. External audit of providers of the Cervical Cancer Prevention Programme in Poland in 2016/2017. Nowotwory. Journal of Oncology. 2018; 68(2): 65–78.
  12. Bao HL, Wang LH, Wang LM, et al. Zhonghua Liu Xing Bing Xue Za Zhi. 2018; 39(2): 208–212.
  13. Acera A, Manresa JM, Rodriguez D, et al. Increasing Cervical Cancer Screening Coverage: A Randomised, Community-Based Clinical Trial. PLoS One. 2017; 12(1): e0170371.
  14. Kurt G, Akyuz A. Evaluating the Effectiveness of Interventions on Increasing Participation in Cervical Cancer Screening. J Nurs Res. 2019; 27(5): e40.
  15. Koliopoulos G, Nyaga VN, Santesso N, et al. Cytology versus HPV testing for cervical cancer screening in the general population. Cochrane Database Syst Rev. 2017; 8: CD008587.
  16. Wojtyla C, Ciebiera M, Kowalczyk D, et al. Cervical Cancer Mortality in East-Central European Countries. Int J Environ Res Public Health. 2020; 17(13).
  17. Pikala M, Burzyńska M, Maniecka-Bryła I. Years of Life Lost Due to Cervical Cancer in Poland in 2000 to 2015. Int J Environ Res Public Health. 2019; 16(9).
  18. Nowakowski A, Śliwczyński A, Seroczyński P, et al. Reimbursed Costs of Management of Uterine Cervical Lesions in Poland--a Descriptive Analysis of Data from the National Health Fund and the Ministry of Health. Cent Eur J Public Health. 2016; 24(2): 163–168.
  19. Pendrith C, Thind A, Zaric GS, et al. Costs of cervical cancer treatment: population-based estimates from Ontario. Curr Oncol. 2016; 23(2): e109–e115.
  20. Sobczyk K, Woźniak-Holecka J, Holecki T, et al. The organization and financing of cervical cancer prevention carried out by midwives in primary health care. Ginekol Pol. 2016; 87(12): 798–804.
  21. Mezei AK, Armstrong HL, Pedersen HN, et al. Cost-effectiveness of cervical cancer screening methods in low- and middle-income countries: A systematic review. Int J Cancer. 2017; 141(3): 437–446.
  22. Campos NG, Maza M, Alfaro K, et al. The cost-effectiveness of implementing HPV testing for cervical cancer screening in El Salvador. Int J Gynaecol Obstet. 2019; 145(1): 40–46.
  23. Pista A, Costa C, Saldanha C, et al. Budget impact analysis of cervical cancer screening in Portugal: comparison of cytology and primary HPV screening strategies. BMC Public Health. 2019; 19(1): 235.
  24. Diaz M, Moriña D, Rodríguez-Salés V, et al. Moving towards an organized cervical cancer screening: costs and impact. Eur J Public Health. 2018; 28(6): 1132–1138.
  25. Sawaya GF, Sanstead E, Alarid-Escudero F, et al. Estimated Quality of Life and Economic Outcomes Associated With 12 Cervical Cancer Screening Strategies: A Cost-effectiveness Analysis. JAMA Intern Med. 2019; 179(7): 867–878.
  26. Gliniewicz A, Zielińska A, Kwiatkowska K, et al. Survival in women diagnosed with breast and cervical cancer in Poland – compared to European countries, based on CONCORD - 3 Programme. Przegl Epidemiol. 2018; 72(4): 499–508.
  27. Dubas-Jakóbczyk K, Kocot E, Seweryn M, et al. Production lost due to cervical cancer in Poland in 2012. Med Pr. 2016; 67(3): 289–299.
  28. Bianchi FP, Gallone MS, Fortunato F, et al. Epidemiology and cost of cervical cancer care and prevention in Apulia (Italy), 2007/2016. Ann Ig. 2018; 30(6): 490–501.
  29. Chesson HW, Meites E, Ekwueme DU, et al. Updated medical care cost estimates for HPV-associated cancers: implications for cost-effectiveness analyses of HPV vaccination in the United States. Hum Vaccin Immunother. 2019; 15(7-8): 1942–1948.
  30. Wolff E, Elfström KM, Haugen Cange H, et al. Cost-effectiveness of sex-neutral HPV-vaccination in Sweden, accounting for herd-immunity and sexual behaviour. Vaccine. 2018; 36(34): 5160–5165.



Nowotwory. Journal of Oncology